Dr. Thomas E. Sepe, MD
Gastroenterology (Gastroenterology Physician)
33 Staniford St
Providence, RI 02905
Who else practices at this address →
Providence County includes mental health (6% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 533
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Icahn School of Medicine at Mount Sinai
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
RI license 8371
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Miriam Hospital Providence, RI
- Southcoast Hospitals Group Fall River, MA
Medical groups
- University Gastroenterology, LLC (102 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 533
- Services billed
- 935
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 274 | 226 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 132 | 131 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 132 | 129 |
| Biopsy of large bowel using a flexible endoscope | 119 | 118 |
| Established patient office or other outpatient visit, 20-29 minutes | 98 | 96 |
| Telephone medical discussion with physician, 11-20 minutes | 93 | 79 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 87 | 86 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 36 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 25 | 25 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 226 payments worth $115,069 in total to this clinician.
| Compensation for services other than consulting (speaking, faculty) | $101,872 |
|---|---|
| Food and Beverage | $7,015 |
| Travel and Lodging | $5,125 |
| Consulting Fee | $1,058 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc May 21, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Ipsen Biopharmaceuticals, Inc Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Madrigal Pharmaceuticals Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Gilead Sciences, Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4113814;AHM;10016843 | $4,930 |
| Gilead Sciences, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4113776;AHM;10016843 | $4,930 |
| Gilead Sciences, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4262953;AHM;10016843 | $4,930 |
| Gilead Sciences, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4268757;AHM;10016843 | $4,930 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,131 |
| Madrigal Pharmaceuticals Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
All 39 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Dec 15, 2025 | Consulting Fee | $1,058 |
| Gilead Sciences, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4263876;AHM;10016843 | $1,900 |
| Madrigal Pharmaceuticals Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4268757;AHM;10016843 | $4,930 |
| Gilead Sciences, Inc. Nov 17, 2025 | Travel and Lodging travel to West Hartford, CT · in-kind Company’s description;4327896;AHM;10016843 | $559 |
| Ipsen Biopharmaceuticals, Inc Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Gilead Sciences, Inc. Nov 5, 2025 | Travel and Lodging travel to Salem, NH · in-kind Company’s description;4327589;AHM;10016843 | $559 |
| Madrigal Pharmaceuticals Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4256461;AHM;10016843 | $1,895 |
| Gilead Sciences, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4249391;GTF;10016843 | $600 |
| Gilead Sciences, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4262953;AHM;10016843 | $4,930 |
| Gilead Sciences, Inc. Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4178732;AHM;10016843 | $3,790 |
| Madrigal Pharmaceuticals Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,754 |
| Madrigal Pharmaceuticals Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,115 |
| Gilead Sciences, Inc. Jul 9, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Worcester, MA · in-kind Company’s description;4328186;AHM;10016843 | $412 |
| Gilead Sciences, Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4113956;AHM;10016843 | $2,370 |
| Gilead Sciences, Inc. Jun 4, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to New Haven, CT · in-kind Company’s description;4327929;AHM;10016843 | $550 |
| Ipsen Biopharmaceuticals, Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,377 |
| Ipsen Biopharmaceuticals, Inc May 21, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Gilead Sciences, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4113776;AHM;10016843 | $4,930 |
| Gilead Sciences, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4136316;AHM;10016843 | $3,790 |
| Ipsen Biopharmaceuticals, Inc May 21, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Hartford, CT · in-kind | $1,148 |
| Madrigal Pharmaceuticals May 14, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Gilead Sciences, Inc. May 9, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chestnut Hill, MA · in-kind Company’s description;4327721;AHM;10016843 | $466 |
| Ipsen Biopharmaceuticals, Inc Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Gilead Sciences, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) Vemlidy · HBV Company’s description;4040422;GTF;10016843 | $2,710 |
| Gilead Sciences, Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4113814;AHM;10016843 | $4,930 |
| Madrigal Pharmaceuticals Apr 8, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4125246;AHM;10016843 | $3,790 |
| Gilead Sciences, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4125719;AHM;10016843 | $3,790 |
| Madrigal Pharmaceuticals Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Mar 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CONCORD, MA · in-kind | $84.00 |
| Madrigal Pharmaceuticals Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026714;GTF;10016843 | $569 |
| Gilead Sciences, Inc. Feb 24, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Falmouth, ME · in-kind Company’s description;4328112;AHM;10016843 | $779 |
| Gilead Sciences, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4110323;AHM;10016843 | $3,790 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,131 |
| Madrigal Pharmaceuticals Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.